Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01148537 · ClinicalTrials.gov registry record · Phase 1
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers
A Phase 1 study of Healthy Volunteers, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT01148537 is a Phase 1 study of Healthy Volunteers that has completed, run by Purdue Pharma. The registered enrollment target is 132 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01148537, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effect of buprenorphine on QT interval corrected for heart rate (QTc) in healthy subjects.
Conditions Studied
Interventions
- DRUG Buprenorphine transdermal patch
- DRUG Matching placebo transdermal patch
- DRUG Avelox (moxifloxacin hydrochloride) tablet
Study Locations (1)
Texas
- PPD Development, LP, Clinics - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2004-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01148537
The ClinicalTrials.gov registry entry for NCT01148537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (73% lower). The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Buprenorphine transdermal patch is the first listed.
NCT01148537 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01148537 about?
NCT01148537 is a clinical study titled "The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers". The purpose of this study is to examine the effect of buprenorphine on QT interval corrected for heart rate (QTc) in healthy subjects.
What is the current status of trial NCT01148537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2004-07. Estimated completion is 2004-12.
What conditions does trial NCT01148537 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT01148537?
The interventions under investigation include: Buprenorphine transdermal patch (DRUG), Matching placebo transdermal patch (DRUG), Avelox (moxifloxacin hydrochloride) tablet (DRUG).
Who is sponsoring clinical trial NCT01148537?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01148537 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.